Kidney Cancer Trial, Recruiting NCT05214885 Sponsor: Qianfoshan Hospital Condition: Kidney Cancer
Back to Kidney Cancer

Kidney Cancer Trial, Recruiting

NCT05214885
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People whose age and sex match those of the kidney cancer patient group being studied (the trial site will determine this match)
  • People who have no tumours in the kidneys, elsewhere in the body, or in the blood system
  • People who have no benign (non-cancerous) kidney conditions, such as kidney stones, diabetic kidney disease, kidney inflammation, or kidney failure
  • People who have no inflammatory diseases anywhere in the body
  • People whose liver, kidney, and heart are all functioning normally

Who may not be able to join:

  • People who have a tumour in the kidney, anywhere else in the body, or in the blood system
  • People who have a non-cancerous kidney condition, such as kidney stones, diabetic kidney disease, kidney inflammation, or kidney failure
  • People who have an inflammatory disease anywhere in the body

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Li Zhang, Dr., The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital

Phone: +86-531-89269680

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Qianfoshan Hospital
Registry
ClinicalTrials.gov
Start date
11 February 2022
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Detection of novel biomarkers in ccRCC patients before surgery; Detection of novel biomarkers in ccRCC patients 1 week after surgery; Detection of novel biomarkers in ccRCC patients at 6 months after surgery; Detection of novel biomarkers in the control groups as baseline

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov